|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/4245 | |
| A61K 39/395 | |||
| A61K 45/06 | |||
| A61P 35/00 |
| (11) | Patento numeris | 3102237 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15746743.2 |
| Europos patento paraiškos padavimo data | 2015-02-03 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-12-14 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-12-02 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2015/014247 |
| Data | 2015-02-03 |
| (87) | Numeris | WO 2015/119944 |
| Data | 2015-08-13 |
| (30) | Numeris | Data | Šalis |
| 201461935714 P | 2014-02-04 | US |
| (72) |
LEOPOLD, Lance, US
KAUFMAN, David, US
|
| (73) |
Merck Sharp & Dohme Corp.,
126 East Lincoln Avenue, Rahway, NJ 07065-0907,
US
Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, US |
| (54) | COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER |
| COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER |